Sarepta Therapeutics Cash Flow - Quarterly (NASDAQ:SRPT)

Add to My Stocks
$35.81 $1.79 (5.26%) SRPT stock closing price Apr 25, 2017 (Closing)

The Sarepta Therapeutics cash flow statement helps investors understand how well the company is managing its cash flows. The profit-loss statement shows Sarepta Therapeutics profits, the balance sheet shows Sarepta Therapeutics debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. The cash flow statement is essetial while conducting the Sarepta Therapeutics cash flow analysis and can be used to measure the operating performance of Sarepta Therapeutics compared to various industry peers like BPMC stock and HALO stock. Sarepta Therapeutics has a positive cash and cash equivalents change of $42.11M. View details of Sarepta Therapeutics cash flows for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2
Sarepta Therapeutics Net Income Cash Flow
-267.26M-178.81M-59.77M-220.03M-155.34M-103.41M-61.55M-135.78M-91.37M-62.14M
Depreciation Depletion Amortization Cash-Flow5.69M4.42M1.63M5.89M4.68M3.18M1.59M6.12M4.34M2.61M
Net Increase (Decrease) in Assets Liabilities-15.76M-13.83M-9.4M31.98M6.51M8.12M2.32M-22.13M-33.5M-25.24M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net31.52M23.64M6.85M32.68M25.94M20.21M14.28M23.26M17.44M17.01M
Sarepta Therapeutics Net Cash from (used by) Operating Activities
-245.82M-164.58M-60.68M-149.46M-118.19M-71.87M-43.34M-128.53M-103.09M-67.76M
Increase (Decrease) in Prop Plant And Equipment-5.34M-2.42M-1.16M-3.4M-2.31M-1.16M-0.53M-25.44M-22.3M-9.84M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments-83.32M112.1M21M13.24M81.52M49.01M44.75M-132.2M-182.34M-174.69M
Other Cash Inflow (Outflow) from Investment Activities-1.52M-1.09M-0.41M-1.43M-0.98M-0.64M-0.39M-1.38M-1.06M-0.62M
Sarepta Therapeutics Net Cash from (used by) Invesment Activities
-90.19M108.58M19.42M8.41M78.22M47.21M43.82M-159.03M-205.7M-185.16M
Issuance (Purchase) of Equity Shares385.73M375.91M1.48M130.8M5.2M0.97M0.43M104.24M104.2M98.77M
Issuance (Repayment) of Debt Securities-7.6M-5.07M-2.52M17M17.02M19.68M-0.02M-0.09M-0.07M-0.04M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Sarepta Therapeutics Net Cash from (used by) Financing Activities
378.12M370.84M-1.03M147.8M22.23M20.65M0.4M104.15M104.13M98.72M
Effect of Exchange Rate Changes on Cash----------
Sarepta Therapeutics Net Change in Cash & Cash Equivalents
42.11M314.83M-42.3M6.75M-17.73M-4.01M0.88M-183.41M-204.66M-154.21M
Cash & Equivalents at Beginning of Year80.3M73.55M187.66M39.9M33.58M48.27M11.19M24.8M20.15M34.59M
Cash & Equivalents at Year End122.42M395.14M38M80.3M55.81M69.53M74.43M73.55M52.29M102.75M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Cash flow for another ticker

1:11
SRPT
The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Sarepta Therapeutics stock price history and Sarepta Therapeutics stock comparison chart inevitably reflect its cash flow situation.
  • Sarepta Therapeutics has cash of $122.42M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Sarepta Therapeutics stock price.
  • Sarepta Therapeutics decreased its cash from operating activities to $81.24M in 2016-Q4. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash from investing stood at a negative value of $-90.19M for SRPT stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Cash flow from financing activities shows the flow of cash between Sarepta Therapeutics and its owners and creditors and was $378.12M for 2016-Q4. Financing activities allow a company to raise capital, and repay bondholders.
.

Key Financial Ratios For Sarepta Therapeutics Cash Flow

FCF margin
-3.88